David R. Valdecanas - Concepedia

Author

David R. Valdecanas

The University of Texas MD Anderson Cancer Center

Also Known As

D R Valdecanas, D Valdecanas, D. Valdecanas, D.R. Valdecanas, David R Valdecanas, David R. Valdecanas, David Valdecanas

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Mirna Therapeutics (United States)First Hospital of China Medical University Wellesley College Pfizer (United States)

About

David R. Valdecanas is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	731
2	Health Sciences	3	3	141
3	Engineering	1	1	28
4	Biomedical Engineering	1	1	28
5	Biomolecular Engineering	1	1	28

David R. Valdecanas

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
PDL1 Regulation by p53 via miR-34 María Angélica Cortez, Cristina Ivan, David R. Valdecanas, JNCI Journal of the National Cancer Institute	2015	657
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy Xiaohong Wang, Jonathan E. Schoenhals, Ailin Li, Cancer Research	2016	264
Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer María Angélica Cortez, David R. Valdecanas, Xiaochun Zhang, Molecular Therapy Mir-200 MirnasOncogenic AgentMedicineBronchial NeoplasmOxidative Stress Response	2014	192
Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy Kathryn A. Mason, Hisanori Ariga, Robert E. Neal, Clinical Cancer Research	2005	151
CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation Luka Milas, Kathryn A. Mason, Hisanori Ariga, Cancer Research	2004	149
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells Ailin Li, Hampartsoum B. Barsoumian, Jonathan E. Schoenhals, Cancer Letters OncologyOncogenic AgentMedicineImmunologyPharmacology	2018	90
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation Li Wang, Kathy A. Mason, K. Kian Ang, Investigational New Drugs Tumor BiologyHuman LungMedicinePharmacologyBreast Cancer Xenografts	2011	83
Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <i>In Vivo</i> and <i>In Vitro</i> Daisuke Sano, Fumihiko Matsumoto, David R. Valdecanas, Clinical Cancer Research	2011	75
In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation María Angélica Cortez, David R. Valdecanas, Sharareh Niknam, Molecular Therapy — Nucleic Acids	2015	70
130-nm Albumin–Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Nicole Wiedenmann, David R. Valdecanas, Nancy Hunter, Clinical Cancer Research	2007	67

Page 1